Etelcalcetide Patent Expiration
Etelcalcetide is Used for treating secondary hyperparathyroidism. It was first introduced by Kai Pharmaceuticals Inc A Wholly Owned Subsidiary Of Amgen Inc
Etelcalcetide Patents
Given below is the list of patents protecting Etelcalcetide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Parsabiv | US10344765 | Stable liquid formulation of AMG 416 (etelcalcetide) | Jun 27, 2034 | Kai Pharms Inc |
| Parsabiv | US11162500 | Stable liquid formulation of AMG 416 (etelcalcetide) | Jun 27, 2034 | Kai Pharms Inc |
| Parsabiv | US11959486 | Stable liquid formulation of AMG 416 (etelcalcetide) | Jun 27, 2034 | Kai Pharms Inc |
| Parsabiv | US9820938 | Stable liquid formulation of AMG 416 (etelcalcetide) | Jun 27, 2034 | Kai Pharms Inc |
| Parsabiv | US8999932 | Therapeutic agents for reducing parathyroid hormone levels | Feb 07, 2031 | Kai Pharms Inc |
| Parsabiv | US8377880 | Therapeutic agents for reducing parathyroid hormone levels | Jul 29, 2030 | Kai Pharms Inc |
| Parsabiv | US9278995 | Therapeutic agents for reducing parathyroid hormone levels | Jul 29, 2030 | Kai Pharms Inc |
| Parsabiv | US9701712 | Therapeutic agents for reducing parathyroid hormone levels | Jul 29, 2030 | Kai Pharms Inc |
Etelcalcetide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List